BA
TCRT icon

BlackRock Advisors’s Alaunos Therapeutics TCRT Stock Holding History

BlackRock Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$948K Buy
1,181
+97
+9% +$87.4K ﹤0.01% 1883
2016
Q3 		$915K Buy
1,084
+34
+3% +$27.3K ﹤0.01% 1866
2016
Q2 		$865K Buy
1,050
+27
+3% +$29.4K ﹤0.01% 1823
2016
Q1 		$1.14M Buy
1,023
+23
+2% +$23.5K ﹤0.01% 1676
2015
Q4 		$1.25M Buy
1,000
+222
+29% +$367K ﹤0.01% 1614
2015
Q3 		$1.05M Sell
778
-91
-10% -$150K ﹤0.01% 1657
2015
Q2 		$1.56M Buy
869
+459
+112% +$713K ﹤0.01% 1383
2015
Q1 		$663K Buy
410
+82
+25% +$122K ﹤0.01% 1865
2014
Q4 		$249K Sell
328
-36
-10% -$19.1K ﹤0.01% 2483
2014
Q3 		$144K Sell
364
-6
-2% -$2.89K ﹤0.01% 2800
2014
Q2 		$224K Sell
370
-44
-11% -$24.5K ﹤0.01% 2565
2014
Q1 		$284K Buy
414
+31
+8% +$20.8K ﹤0.01% 2442
2013
Q4 		$249K Buy
383
+79
+26% +$47K ﹤0.01% 2522
2013
Q3 		$180K Hold
304
– – ﹤0.01% 2620
2013
Q2 		$96K Buy
+304
New +$84.4K ﹤0.01% 2924

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Advisors's TCRT Position: Q4 2016 in Review

BlackRock Advisors increased its Alaunos Therapeutics (TCRT) stake by 8.9% in Q4 2016, buying an estimated $87.4K and bringing the position to 1,181 shares worth $948K. The position accounts for ﹤0.01% of the portfolio, ranked #1883.

BlackRock Advisors first reported a position in TCRT in Q2 2013 and has held it in 15 quarters since. The position peaked at $1.56M in Q2 2015. 136 funds tracked by Wall St. Rank hold TCRT as of Q4 2016.

  • BlackRock Advisors held 1,181 shares of Alaunos Therapeutics worth $948K as of Q4 2016.
  • BlackRock Advisors bought 97 Alaunos Therapeutics shares in Q4 2016, an estimated $87.4K.
  • Alaunos Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1883 holding.
  • BlackRock Advisors first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Alaunos Therapeutics position peaked at $1.56M in Q2 2015.
  • 136 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.